1252477

Devalingam Mahalingam, M.D., Ph.D. — FEI 3031824073

Inspection Details

Classification
Official Action Indicated (OAI) (OAI)
End Date
October 18, 2024
Fiscal Year
2025
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Chicago, IL (United States)

Additional Details

Clinical Investigator (CI)

Citations

IDCFRDescription
723021 CFR 50.27(b)(2)Short form: Oral presentation/signing
756021 CFR 312.60FD-1572, protocol compliance